Therapy Detail

Therapy Name R3Mab
Therapy Description

R3Mab is a monoclonal antibody, which specifically targets FGFR3 to block signaling and tumor growth (PMID: 23657946, PMID: 19381019)

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
R3Mab FGFR3 Inhibitor 12 R3Mab is a monoclonal antibody, which specifically targets FGFR3 to block signaling and tumor growth (PMID: 23657946, PMID: 19381019)
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
FGFR3 R248C Advanced Solid Tumor sensitive R3Mab Preclinical - Cell culture Actionable In a preclinical study, R3Mab inhibited ligand-independent proliferation induced by FGFR3 R248C in cultured cells (PMID: 19381019). 19381019
FGFR3-TACC3 urinary bladder cancer sensitive R3Mab Preclinical - Cell line xenograft Actionable In a preclinical study, R3Mab inhibited FGFR3 signaling and tumor growth in bladder cancer cell line xenograft models harboring FGFR3-TACC3 (PMID: 25326231). 25326231
FGFR3 S249C Advanced Solid Tumor sensitive R3Mab Preclinical - Cell culture Actionable In a preclinical study, R3Mab inhibited proliferation of transformed cells expressing FGFR3 S249C in culture (PMID: 19381019). 19381019
FGFR3 S249C bladder carcinoma sensitive R3Mab Preclinical - Cell line xenograft Actionable In a preclinical study, R3Mab decreased dimer formation and constitutive activation of FGFR3 S249C, and inhibited growth of bladder cancer cell lines harboring FGFR3 S249C in culture and in xenograft models (PMID: 19381019). 19381019
FGFR3 wild-type bladder carcinoma sensitive R3Mab Preclinical - Cell line xenograft Actionable In a preclinical study, R3Mab decreased wild-type FGFR3 activation, thereby inhibited cell proliferation of FGFR3 wild-type human bladder cancer cells in culture and in cell line xenograft models (PMID: 19381019). 19381019
FGFR3 G372C Advanced Solid Tumor sensitive R3Mab Preclinical - Cell culture Actionable In a preclinical study, R3Mab inhibited ligand-dependent proliferation in cells expressing FGFR3 G372C (PMID: 19381019). 19381019
FGFR3 Y375C Advanced Solid Tumor sensitive R3Mab Preclinical - Cell culture Actionable In a preclinical study, R3Mab inhibited ligand-dependent proliferation of cells expressing FGFR3 Y375C in culture (PMID: 19381019). 19381019
FGFR3 K652E Advanced Solid Tumor sensitive R3Mab Preclinical - Cell culture Actionable In a preclinical study, R3Mab inhibited ligand-dependent cell proliferation in cells expressing FGFR3 K652E in culture (PMID: 19381019). 19381019
Clinical Trial Phase Therapies Title Recruitment Status